NASDAQ: $EWTX
Edgewise Therapeutics Reports Inducement Grants as Permitted by Nasdaq Listing Rules
Edgewise Therapeutics, Inc., a company focused on developing transformative therapies for muscular dystrophies, has recently announced the issuance of new equity awards. These grants were made as inducement awards to newly hired non-executive employees, a practice fully compliant with the Nasdaq Stock Market Listing Rule 5635(c).
Details of the Inducement Grants
In accordance with the terms of the Nasdaq rules, these inducement grants do not require stockholder approval. The grants were approved by the Compensation Committee of the Board of Directors of Edgewise Therapeutics. The awards were made to the non-executive employees who joined the company in connection with a recent business transaction that triggered the exemption provided by Nasdaq Listing Rule 5635(c).
Specifically, the grants consist of restricted stock units (RSUs). A total of 15,600 shares of common stock are subject to the RSU awards. These RSUs vest over a period of three years, subject to the employees’ continued service with the company.
Purpose and Compliance
Inducement grants are a standard mechanism used by companies listed on Nasdaq to attract and retain key talent following significant corporate events. By utilizing the exemption under Rule 5635(c), Edgewise Therapeutics ensures it can provide competitive compensation packages to its newest team members without unnecessary delay or complex procedural requirements related to stockholder votes.
The company confirmed that all procedural requirements stipulated by Nasdaq for issuing these types of inducement awards have been strictly followed. This action underscores Edgewise Therapeutics’ commitment to building a robust team capable of advancing its pipeline of treatments, particularly in the challenging field of muscular dystrophies.
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for genetically defined muscle diseases. The company’s lead program targets Duchenne muscular dystrophy (DMD) and other dystrophies caused by specific mutations.
These recent personnel additions, supported by the issuance of these inducement grants, are critical as the company moves its differentiated therapeutic candidates through clinical stages and prepares for future growth and operational expansion.